Similar articles

• BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy.

  Deighton C, Hyrich K, Ding T, Ledingham J, Lunt M, Luqmani R, Kiely P, Bukhari M, Abernethy R, Ostor A, Bosworth A, Gadsby K, McKenna F, Finney D, Dixey J; BSR Clinical Affairs Committee & Standards, Audit and Guidelines Working Group and the BHPR. Deighton C, et al. Rheumatology (Oxford). 2010 Jun;49(6):1197-9. doi: 10.1093/rheumatology/keq006a. Epub 2010 Mar 22. Rheumatology (Oxford). 2010. PMID: 20308121 No abstract available.
• NICE reviews its guidance against sequential use of anti-TNF drugs for arthritis.

  Mayor S. Mayor S. BMJ. 2007 Jun 16;334(7606):1238-9. doi: 10.1136/bmj.39245.417292.DB. BMJ. 2007. PMID: 17569907 Free PMC article. No abstract available.
• NICE guidelines on anti-tumor necrosis factor therapy for RA.

  Scott DL, Steer S. Scott DL, et al. Nat Clin Pract Rheumatol. 2009 Jan;5(1):16-7. doi: 10.1038/ncprheum0964. Epub 2008 Dec 2. Nat Clin Pract Rheumatol. 2009. PMID: 19048006 No abstract available.
• Tocilizumab for rheumatoid arthritis.

  [No authors listed] [No authors listed] Drug Ther Bull. 2010 Jan;48(1):9-12. doi: 10.1136/dtb.2009.08.0033. Drug Ther Bull. 2010. PMID: 20040568 Review.
• Therapy: The NICE position on indications for biologics and biosimilars.

  Scheinberg M, Gomez-Reino JJ. Scheinberg M, et al. Nat Rev Rheumatol. 2016 May;12(5):255-6. doi: 10.1038/nrrheum.2016.56. Epub 2016 Apr 15. Nat Rev Rheumatol. 2016. PMID: 27080695 Review. No abstract available.